Quest Partners LLC Has $305,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Quest Partners LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 239.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,567 shares of the company’s stock after acquiring an additional 3,223 shares during the quarter. Quest Partners LLC’s holdings in Moderna were worth $305,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the 2nd quarter worth approximately $26,000. Family Firm Inc. bought a new stake in Moderna in the 2nd quarter valued at $33,000. Bank & Trust Co acquired a new position in Moderna in the 2nd quarter valued at $36,000. Hanseatic Management Services Inc. acquired a new position in Moderna in the 2nd quarter valued at $48,000. Finally, Plato Investment Management Ltd grew its holdings in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after buying an additional 288 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

NASDAQ:MRNA opened at $43.66 on Tuesday. The stock’s 50-day simple moving average is $54.96 and its 200 day simple moving average is $93.71. The firm has a market capitalization of $16.80 billion, a PE ratio of -7.50 and a beta of 1.69. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.39) earnings per share. On average, analysts anticipate that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, November 8th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Finally, Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $84.00.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 13.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 2,930 shares of company stock worth $217,170. 15.20% of the stock is currently owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.